Drug News


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		AlzSWAN
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Biomarkers
		Mutations
		Protocols
		Research Models
		Video Gallery
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: News

Drug News

Search by keywords and publication date

Keywords:

any keywords all keywords

Pub Date:

From


Search Results:

1 to 25 of 282 results

Paper Alert: Antisense Oligonucleotide Therapy Safe for ALS?
9 May 2013. An oligonucleotide designed to tamp down an enzyme that causes amyotrophic lateral sclerosis seems safe...

Gammagard™ Misses Endpoints in Phase 3 Trial
8 May 2013. Topline data yesterday showed that intravenous immunoglobulin (IVIG) therapy, known as Gammagard™, failed to meet primary endpoints of slowing cognitive and functional decline...

Anti-Amyloid Results Show Modest Benefits, Mild Side Effects
1 April 2013. Scientists continue to squeeze every last bit of information out of Phase 3 trials for anti-amyloid antibodies solanezumab and bapineuzumab...

Does TauRx Drug Work by Oxidizing Tau?
21 February 2013. In 2008, methylene blue created a stir when the drug’s sponsors reported that it slowed cognitive decline, while other scientists questioned that interpretation...

Paper Alert—HORIZON Trial Data Published
22 January 2013. Researchers have formally published the results of the Phase 3 trial of Dimebon®, aka latrepirdine, in Huntington’s disease patients...

Cut to the Chase: Therapies Go Directly to Central Nervous System
22 January 2013. A growing number of neurosurgeons are inserting needles, catheters, and capsules into the brain or spinal cord, hoping to alleviate AD and other neurodegenerative conditions...

NIH Funds Four Clinical Trials in ADCS Renewal
18 January 2013. The National Institutes of Health announced that it will fund the Alzheimer’s Disease Cooperative Study to conduct four new clinical studies over the next five years...

Solanezumab Selected for Alzheimer’s A4 Prevention Trial
18 January 2013. Researchers announced the selection of solanezumab as the first therapeutic drug to be evaluated in the A4 prevention clinical trial...

Alzforum’s Top 12 of 2012
31 December 2012. Here’s hoping that this year’s 12 trends of Alzheimer’s may have staying power—enough to put the search for therapies on a stronger footing...

Tau-Targeting Drug Davunetide Washes Out in Phase 3 Trials
21 December 2012. Allon Therapeutics Inc. announced that its drug candidate davunetide failed to show efficacy for progressive supranuclear palsy (PSP) in a Phase 2/3 trial...

Q&A With Merck’s Johan Luthman
14 December 2012. Merck’s BACE inhibitor development program began enrolling last month for an 18-month Phase 2/3 trial of its lead compound (MK-8931) in mild to moderate AD...

Solanezumab Heads for New Phase 3 Trial
13 December 2012. Eli Lilly announced yesterday that it plans to conduct a new Phase 3 trial of its anti-amyloid antibody, solanezumab...

Drug Company Halts Development of γ-Secretase Inhibitor Avagacestat
11 December 2012. Bristol-Myers Squibb recently announced that it will halt all clinical development of its γ-secretase inhibitor avagacestat...

Merck Launches Largest Trial of BACE Inhibitor in AD
7 December 2012. Merck announced this week that it has begun enrolling for the largest clinical trial of a β-secretase (BACE1) inhibitor in Alzheimer’s disease patients...

Déjà Vu? AD Patients Again Look Worse on γ-Secretase Inhibitor
21 November 2012. In a Phase 2 trial of avagacestat, AD patients who took high doses suffered more adverse effects and appeared to fare worse cognitively than those on placebo...

DIAN Trial Picks Gantenerumab, Solanezumab, Maybe BACE Inhibitor
10 October 2012. Today, scientists of DIAN's Trials Unit announced their drug choices for trials to try to prevent dementia in people who have inherited autosomal-dominant mutations...

The Solanezumab Benefit: Oh, So Small, But Probably Real
9 October 2012. Prospects for Alzheimer’s immunotherapy appear to have brightened...

Bapineuzumab Phase 3: Target Engagement, But No Benefit
12 September 2012. Bapineuzumab prevents accumulation of Aβ in the brain and lowers phospho-tau (p-tau) in cerebrospinal fluid (CSF), according to analysis...

Paper Alert—GuidAge Trial Data on Ginkgo Biloba Published
11 September 2012. It did not pass muster in a large clinical trial in the U.S., and now a similar study in Europe concludes that ginkgo biloba extract does nothing to prevent the onset of AD...

Phase 3 Solanezumab Trials "Fail"—Is There a Silver Lining?
24 August 2012. Eli Lilly and Company announced today that solanezumab did not reach its primary endpoints in either of two trials in patients with mild to moderate AD...

Anticonvulsants Reverse AD-like Symptoms in Transgenic Mice
14 August 2012. Could anti-epileptic drugs be the next hope for treating and even preventing Alzheimer’s disease symptoms?...

Clinical Trials of Intravenous Bapineuzumab Halted
8 August 2012. Janssen Alzheimer Immunotherapy will discontinue all studies of intravenous bapineuzumab, an amyloid-β antibody, in patients with mild to moderate Alzheimer’s disease...

Q&A With Roche’s CNS Leader Luca Santarelli
25 July 2012. Gabrielle Strobel met up with Luca Santarelli, who has moved into drug discovery research at Roche/Genentech and now oversees the AD therapy development program, among others...

No Pony in There: Bapi Fails Mild to Moderate ApoE4 Carriers
23 July 2012. Pfizer conceded that results of the first of four Phase 3 trials of intravenous bapineuzumab failed to meet its co-primary endpoints in patients with mild to moderate AD...

Novel Drug Knocks Aβ Off Synapses, Reduces Toxicity
20 July 2012. In AD therapy, it may be time for an alternative target to shine: the α7 nicotinic acetylcholine receptor...

1 to 25 of 282 results

Print this page

Email this page

Alzforum News

Papers of the Week

Text size

Share & Bookmark

Most E-mailed

Most Commented

Last 7 Days

Last 30 Days

Not Seeing Eye to Eye: Do Lenses Accumulate Aβ?

Gammagard™ Misses Endpoints in Phase 3 Trial

Guidelines at Nature Aim to Stem Tide of Irreproducibility

Paper Alert: Antisense Oligonucleotide Therapy Safe for ALS?

New Assays for Aβ Oligomers in CSF Claim Femtogram Sensitivity

Check out our upcoming Webinar: Can Network Analysis Identify Pathological Pathways in Alzheimer’s

See our most recent Webinar: How Cognitive Stimulation Might Protect Against Aβ Oligomers

Check out our Webinar: New Frontier: Developing Outcome Measures for Pre-dementia Trials

See related news on Alzheimer disease on the BioSpace website.

Coalition Against Major Diseases (CAMD)

Visit C-Path's Coalition Against Major Diseases to learn about its collaborative efforts in Alzheimer's and Parkinson's.

AlzGene

PDGene

SZGene

MSGene

ALSGene

An up-to-date collection of all published genetic association studies.

The AlzRisk Epidemiology Database provides a publicly available collection of published studies on the impact of putative environmental risk factors and protective factors related to Alzheimer disease in longitudinal cohort studies.

ADNI Data at LONI

ADNI Information

DIAN

Foundation for the NIH

AddNeuroMed

neuGRID

NYAS Events

View New York Academy of Sciences events (RSS)

NYAS Publications

View New York Academy of Sciences publications (RSS)

Check out Geoffrey Beene Gives Back®'s Rocks Stars of Science campaign to bring rock stars and science idols together to share their passion for global health and disease prevention.

The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.

PIB PET in early AD patient reveals amyloid in cortex and deep brain areas.[Video courtesy of Scott Ziolko and the Pittsburgh Amyloid Imaging Group]